Insulin icodec
| Clinical data | |
|---|---|
| Pronunciation | /ˌɪnsəlɪn ˈaɪkoʊdɛk/ IN-sə-lin EYE-koh-dek |
| Trade names | Awiqli |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a626058 |
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C280H435N71O87S6 |
| Molar mass | 6380.33 g·mol−1 |
Insulin icodec, sold under the brand name Awiqli, is an ultralong-acting basal insulin analogue used in the treatment of diabetes. It is administered by subcutaneous injection once weekly. It was developed by Novo Nordisk.
Insulin icodec was designed to provide basal insulin coverage with once-weekly dosing.
It is approved for medical use in Canada, the European Union, Australia, and in the United States.